The pharmacological and potential therapeutic actions of CBGA are largely unknown, although a recent study from our laboratory demonstrated that CBGA has anticonvulsant properties in both the Scn1a+/- mouse model of Dravet syndrome and in the maximal electroshock (MES) seizure threshold test (Anderson et al. 2021b). The gene discussed is SCN1A; the disease is Dravet syndrome.